A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
Treatment of wild-type human immunodeficiency virus [HIV-1(IIIB)]-infected cell cultures with the thiocarboxanilide UC-781 under low selective pressure (i.e., 0.01 microg/ml) resulted in the emergence of V106A RT mutant virus. On increasing drug concentrations (stepwise up to 30 microg/ml) the virus...
मुख्य लेखकों: | Balzarini, J, Pelemans, H, Esnouf, R, De Clercq, E |
---|---|
स्वरूप: | Journal article |
भाषा: | English |
प्रकाशित: |
1998
|
समान संसाधन
-
Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
द्वारा: Pelemans, H, और अन्य
प्रकाशित: (1998) -
Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol.
द्वारा: Anna Figueiredo, और अन्य
प्रकाशित: (2006-11-01) -
A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
द्वारा: Harrigan, P, और अन्य
प्रकाशित: (2002) -
Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.
द्वारा: Pelemans, H, और अन्य
प्रकाशित: (1997) -
Assessment of Nonnucleoside Inhibitors Binding to HIV-1 Reverse Transcriptase Using HYDE Scoring
द्वारा: Agata Paneth, और अन्य
प्रकाशित: (2019-04-01)